Calla Lily Clinical Care

Calla Lily Clinical Care is a London-based women's health medtech company developing Callavid® — a patented, tampon-shaped drug delivery device that provides leak-free, dosage-confident administration of vaginally-delivered therapeutics. Current vaginal drug delivery methods, primarily pessaries, are prone to significant leakage that causes anxiety and inconvenience for patients at already stressful moments. Callavid is designed to be hygienically inserted, remain in place during drug absorption, and be cleanly removed — addressing a long-standing unmet need.

The company's initial focus is progesterone delivery for miscarriage prevention and IVF support. Following updated NICE guidance in 2021, over 150,000 women in the UK are now eligible for progesterone therapy each year for threatened miscarriage. Callavid received FDA clearance for its underlying technology, was named one of TIME magazine's Best Inventions of the Year, and is progressing towards clinical trials in the UK supported by £1 million in NIHR funding. The platform also has significant potential for oncology, menopause, bacterial vaginosis, and other gynaecological indications.

Founded in 2021 by Thang Vo-Ta and Dr Lara Zibners, Calla Lily Clinical Care is a certified B Corp that has raised £2.3 million in funding and secured over £2 million in Innovate UK and NIHR grants. In February 2026, the company announced a strategic collaboration with Merck — its first industry partnership — to advance the Callavid platform, validating its potential as a transformative drug delivery technology for the global women's health market.